Fonte: Clinical rheumatology. Unidade: FM
Assuntos: ANTICORPOS, CINÉTICA, FATORES DE RISCO, METOTREXATO, PACIENTES
ABNT
BRUNELLI, Juliana Barbosa et al. Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching. Clinical rheumatology, v. 39, n. 2, p. 515-521, 2020Tradução . . Disponível em: https://doi.org/10.1007/s10067-019-04798-6. Acesso em: 23 abr. 2024.APA
Brunelli, J. B., Silva, C. A. A. da, Pasoto, S. G., Saa, C. G. S., Kozu, K. T., Goldenstein-Schainberg, C., et al. (2020). Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching. Clinical rheumatology, 39( 2), 515-521. doi:10.1007/s10067-019-04798-6NLM
Brunelli JB, Silva CAA da, Pasoto SG, Saa CGS, Kozu KT, Goldenstein-Schainberg C, Leon EP, Vendramini MBG, Fontoura N, Bonfa ESD de O. Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching [Internet]. Clinical rheumatology. 2020 ; 39( 2): 515-521.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1007/s10067-019-04798-6Vancouver
Brunelli JB, Silva CAA da, Pasoto SG, Saa CGS, Kozu KT, Goldenstein-Schainberg C, Leon EP, Vendramini MBG, Fontoura N, Bonfa ESD de O. Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching [Internet]. Clinical rheumatology. 2020 ; 39( 2): 515-521.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1007/s10067-019-04798-6